Waiver of Consent vs Waiver of Written Consent
One is very common, the other is rarely granted. Learn the key differences between waiver of consent & waiver of written consent for clinical trials
Unlocking FDA’s Vision for PRO Collection in RWE: Timing, Methods, and Insights
Discover FDA’s guidance on collecting PROs for Real-World Evidence (RWE), focusing on timing, methods, and improving data quality.
Understanding Phase 4 Clinical Trials: A Critical Component of Post-Marketing Insight to Drugs in the Real-World
When it comes to Phase 4 clinical trials, Castor’s cutting-edge Real-World Evidence (RWE) platform is your key to unlocking unprecedented insights. Elevate Your Phase 4 Trials with our user-friendly EDC system that adapts to your unique Phase 4 needs. Effortlessly manage multi-region studies with our flexible platform. Reduce costs and accelerate timelines with our innovative AI solutions. Rest easy with our robust security and compliance features.
5 Key Takeaways from the FDA’s Real-World Evidence Guidance
A deep dive into the evolving regulatory environment, the innovative approaches emerging in RWE, and the critical importance of precise data utilization
Navigating the Evolving Regulatory and Data Landscape
A deep dive into the evolving regulatory environment, the innovative approaches emerging in RWE, and the critical importance of precise data utilization
Do We Still Need Patients in Tomorrow’s Trials? Modeling Placebo Effect and Beyond
Discover the transformative role of AI in clinical trials, with expert insights from Derk Arts and MaryAnne Rizk on ethical and efficient drug development
eCOA: Afterthought or Essential Strategy? An Expert’s View on Choosing and Developing an eCOA Strategy
The Evolving Landscape of eCOA in Clinical Trials Clinical trials have long grappled with the complexities of data…
Evaluating “Bother” as a Component of Patient-Reported Outcomes in Clinical Studies
Patient-reported outcome (PRO) instruments refer to multiple scales and questionnaires designed to collect patients’ personal feedback on their…
Under pressure: what it takes to validate a cuffless blood pressure device
When a company brings a cuffless, continuous blood pressure monitor to market, the wristband is the easy part. The hard part is proving a cloud algorithm can read blood pressure accurately across every kind of person who wears it. In this 2024 session with Castor’s Derk Arts, Aktiia CMO Jay Shah lays out the real evidence bar, from validating accuracy across skin tones, BMI, and gender to why continuous data turns blood pressure into a pattern clinicians can act on. Aktiia now operates as Hilo, with FDA over-the-counter clearance in the US. Watch the conversation on demand.
